Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

LabPoint is a young, growth-oriented healthcare company focused on providing physicians and other customers across Switzerland with high-quality laboratory diagnostic services. The company operates nationwide in the field of laboratory diagnostics and is headquartered in Avenches, Vaud.

Affidea is a leading pan-European provider of specialized healthcare services, particularly in oncology, polyclinics and advanced diagnostic imaging. Founded in 1991, the company operates approximately 342 centers across 15 countries and records more than 14 million patient visits per year.

Lindenhofgruppe is one of Switzerland’s leading privately owned listed hospital groups. Across its three sites in Engeried, Lindenhof and Sonnenhof, more than 172,000 patients are treated annually, including approximately 30,000 inpatients. In addition to comprehensive interdisciplinary basic care, the group offers a broad range of specialized and highly specialized medical services and employs around 2,600 people.

Oaklins’ team in Switzerland acted as the exclusive M&A advisor to the owner of LabPoint. The team supported the entire sales process, from strategic preparation and the identification of suitable investors, through the coordination of due diligence and support during negotiations, to the successful completion of the transaction.